Moderna Stock Is Surging: What's Going On?

Moderna Inc. (NASDAQ: MRNA) shares surged 8.18% to $157.53, continuing a month-long rally that has seen the stock rise over 100%. This increase follows the announcement of positive Phase 3 trial results for a personalized cancer vaccine developed in collaboration with Merck & Co., which demonstrated improved outcomes for high-risk melanoma patients. Despite the stock's recent performance, analysts remain divided, with a consensus rating of 'Hold' and an average price target of $91, significantly below current trading levels.